APOTHECUS PHARMACEUTICAL CORP. Faces Recurring CGMP Violations: VCF Contraceptive (NONOXYNOL-9) Recall Signals Heightened FDA Scrutiny
APOTHECUS PHARMACEUTICAL CORP. faces a Class II voluntary recall of 33,659 retail boxes of VCF CONTRACEPTIVE PRE-FILLED APPLICATORS (NONOXYNOL-9) due to critical CGMP deviations, specifically out-of-specification assay results. This marks a recurring compliance issue for the Hicksville, NY-based manufacturer, impacting supply chains in the USA and Hong Kong. Procurement and regulatory teams must assess immediate product availability risks and long-term supplier reliability, given the pattern of quality control failures.
FDA Identifies Critical CGMP Deviations in VCF Contraceptive Applicators
APOTHECUS PHARMACEUTICAL CORP. has initiated a Class II voluntary recall, reference number D-0151-2025, for its VCF CONTRACEPTIVE PRE-FILLED APPLICATORS, containing the active ingredient NONOXYNOL-9. The primary reason for this recall is identified as Current Good Manufacturing Practice (CGMP) deviations, specifically the product being out of specification for assay. This means the finished product, distributed under NDC 52925-512-10 and 52925-512-25, failed to meet established quality standards for its active ingredient concentration, potentially compromising its efficacy. The recall, initiated on November 22, 2024, and classified by the FDA on December 17, 2024, affects 33,659 retail boxes distributed nationwide across the USA and to two distributors in Hong Kong. For procurement directors, this event necessitates an immediate review of inventory levels and supplier qualification for similar contraceptive products. Regulatory affairs heads must assess the potential impact on product registrations and market authorizations, particularly in affected international markets like Hong Kong, where product quality non-compliance can lead to significant market access challenges. Business development executives should evaluate the competitive landscape as this recall creates a gap in the market for NONOXYNOL-9 based vaginal contraceptives.
APOTHECUS PHARMACEUTICAL CORP.'s Operational Footprint and Product Scope
APOTHECUS PHARMACEUTICAL CORP., identified as the manufacturer and original packager, operates from Hicksville, NY, United States, with distribution noted from Ronkonkoma, NY. The company specializes in Human OTC Drugs, with VCF CONTRACEPTIVE PRE-FILLED APPLICATORS being a key product in its portfolio. These applicators, packaged as 10 pre-filled units with a net weight of 0.09 oz (2.55g) each, are designed for vaginal application. The affected lots, 3A001/3A001A, have an expiration date of July 2025, indicating that products currently in circulation and on shelves are at risk. The broad distribution pattern, covering the entire USA and extending to Hong Kong, underscores the significant reach of Apothecus Pharmaceutical Corp.'s supply chain for this specific product. For supply chain VPs, this highlights the importance of robust quality agreements and audit processes for contract manufacturers, even for OTC products. The recall's scope means that not only domestic but also international distribution channels are impacted, requiring a coordinated response to manage product retrieval and communication with international partners. This event serves as a critical reminder for procurement teams to diversify their supplier base for essential OTC products to mitigate single-source risks.
Supply Chain Exposure: Risks for VCF Contraceptive Distributors
The voluntary recall of VCF CONTRACEPTIVE PRE-FILLED APPLICATORS directly impacts distributors and retailers across the USA and in Hong Kong. With 33,659 retail boxes affected, the immediate consequence is a disruption in the availability of a widely used NONOXYNOL-9 based contraceptive product. Procurement directors must urgently assess their current stock of VCF CONTRACEPTIVE PRE-FILLED APPLICATORS and initiate procedures for product segregation and return. The Class II classification, indicating that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, still carries significant commercial implications. For business development executives, this creates an opportunity to analyze market demand for alternative contraceptive solutions and potentially adjust product portfolios to fill supply gaps. Supply chain VPs should review their risk management frameworks for OTC products, particularly those with a broad distribution footprint, to ensure swift and effective recall execution and minimize market impact. The dual market exposure (USA and Hong Kong) also complicates logistics and regulatory reporting requirements, demanding a sophisticated and agile response from affected stakeholders.
APOTHECUS PHARMACEUTICAL CORP.'s Recurring Compliance Challenges
This latest recall for VCF CONTRACEPTIVE PRE-FILLED APPLICATORS due to CGMP deviations is not an isolated incident for APOTHECUS PHARMACEUTICAL CORP. The company faced a similar Class II recall for its VCF Contraceptive Film due to cGMP deviations, as reported on April 3, 2024. Both events, occurring within months of each other, involve VCF contraceptive products and stem from fundamental quality control failures. This pattern suggests systemic issues within Apothecus Pharmaceutical Corp.'s manufacturing processes and quality management system, rather than isolated batch errors. For regulatory affairs heads, this recurring non-compliance signals a heightened risk profile for Apothecus. The FDA is likely to intensify its scrutiny, potentially leading to more severe enforcement actions beyond voluntary recalls, such as a formal Warning Letter or even an Import Alert for products destined for the US market from their facilities. Procurement directors sourcing any products from Apothecus must re-evaluate their supplier risk assessments, considering the potential for future disruptions and the reputational damage associated with continued association with a non-compliant manufacturer. This history underscores the critical need for robust supplier auditing and continuous monitoring of regulatory intelligence.
Remediation and Future Regulatory Scrutiny for APOTHECUS
As the recall of VCF CONTRACEPTIVE PRE-FILLED APPLICATORS remains ongoing, APOTHECUS PHARMACEUTICAL CORP. is obligated to conduct a thorough investigation into the root cause of the out-of-specification assay results and implement comprehensive corrective and preventive actions (CAPA). The FDA will closely monitor the effectiveness of these actions and the overall recall process. Given the company's recent history of similar CGMP deviations with another VCF contraceptive product, regulatory affairs heads should anticipate a significantly elevated level of FDA oversight. This could manifest as more frequent inspections, requests for detailed remediation plans, or even a formal Warning Letter if the agency deems the company's response inadequate. Supply chain VPs must prepare for potential extended disruptions in the supply of NONOXYNOL-9 based products from Apothecus, as the resolution of systemic quality issues can be a lengthy process. Business development executives should consider the long-term implications for Apothecus's market standing and its ability to secure new contracts or maintain existing ones, especially for sensitive OTC products where consumer trust is paramount. Proactive engagement with alternative suppliers and a clear communication strategy for affected customers will be crucial for mitigating commercial fallout.